Shire has gained European approval for its gaucher disease treatment
The European Commission has granted marketing authorization to Shire plc (Cambridge, MA) for VPRIV (velaglucerase alfa), a human cell line–derived enzyme replacement therapy for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan drug, making it available in 30 countries across Europe.
This approval was based on data from Shire's velaglucerase alfa clinical development program for type 1 Gaucher disease. Over 100 Gaucher patients at 24 sites in 10 countries around the world participated in the clinical studies, all of which met their primary endpoints.
Earlier this year, the US Food and Drug Administration approved VPRIV following priority review to treat children and adults with type 1 Gaucher disease in the United States. VPRIV is an alternative to Cerezyme (imiglucerase), a drug manufactured by Genzyme (Cambridge, MA). Cerezyme currently is in short supply because of manufacturing problems at the Genzyme plants that produce Cerezyme. Because of the Cerezyme shortage, Shire also had received an FDA-approved treatment protocol to allow early patient access to velaglucerase alfa before it was approved.
Previous Coverage
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.